Patient-reported outcomes (PROs) from TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in patients with pretreated HER2-positive advanced breast cancer.
Bartley K, Wildiers H, Kim S, Krop I, Kang J, Yu R, Leung A, Trudeau C, Gonzalez-Martin A. Patient-reported outcomes (PROs) from TH3RESA, a phase 3 study of trastuzumab emtansine (T-DM1) versus treatment of physician’s choice (TPC) in patients with pretreated HER2-positive advanced breast cancer. Journal Of Clinical Oncology 2014, 32: 153-153. DOI: 10.1200/jco.2014.32.26_suppl.153.Peer-Reviewed Original ResearchT-DM1 armNausea/vomitingEORTC QLQ-C30Patient-reported outcomesTPC armT-DM1QLQ-C30HER2-positive advanced breast cancerCox proportional hazards modelEORTC QLQ-BM22Objective response rateAdvanced breast cancerGlobal health statusPhase 3 studyPost-baseline assessmentProgression-free survivalKaplan-Meier methodCycles of treatmentProportional hazards modelImpact of treatmentDistribution of severityQuality of lifePain progressionQLQ-BM22Pain scores